Liquidia Co. (NASDAQ:LQDA) Given Consensus Rating of "Buy" by Analysts

Liquidia Co. (NASDAQ:LQDA - Get Free Report) has received an average rating of "Buy" from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $26.63.

A number of research analysts have issued reports on LQDA shares. Scotiabank reissued an "outperform" rating on shares of Liquidia in a report on Thursday, March 20th. Wells Fargo & Company initiated coverage on Liquidia in a research note on Friday, December 20th. They set an "overweight" rating and a $20.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and set a $29.00 price objective on shares of Liquidia in a report on Thursday, March 20th. Finally, Needham & Company LLC increased their price objective on Liquidia from $19.00 to $25.00 and gave the company a "buy" rating in a report on Thursday, March 20th.

Liquidia Trading Down 1.0 %

LQDA stock traded down $0.15 on Thursday, hitting $15.09. 588,560 shares of the company's stock traded hands, compared to its average volume of 936,085. The stock has a fifty day moving average of $15.10 and a 200-day moving average of $12.44. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of -9.26 and a beta of 0.07. Liquidia has a 1-year low of $8.26 and a 1-year high of $16.81.

Remove Ads

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The firm had revenue of $2.92 million during the quarter, compared to the consensus estimate of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. On average, equities research analysts anticipate that Liquidia will post -1.51 earnings per share for the current fiscal year.

Insider Buying and Selling at Liquidia

In related news, CFO Michael Kaseta sold 23,370 shares of the firm's stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $275,298.60. Following the sale, the chief financial officer now directly owns 401,755 shares of the company's stock, valued at $4,732,673.90. This trade represents a 5.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Roger Jeffs sold 22,343 shares of Liquidia stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $263,200.54. Following the sale, the chief executive officer now directly owns 1,019,177 shares of the company's stock, valued at approximately $12,005,905.06. This trade represents a 2.15 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 71,245 shares of company stock worth $843,326. Corporate insiders own 30.10% of the company's stock.

Hedge Funds Weigh In On Liquidia

Several institutional investors and hedge funds have recently bought and sold shares of LQDA. Steward Partners Investment Advisory LLC bought a new position in shares of Liquidia in the 4th quarter worth approximately $59,000. Summit Investment Advisors Inc. grew its position in Liquidia by 35.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock worth $78,000 after purchasing an additional 1,719 shares during the period. D. E. Shaw & Co. Inc. bought a new position in shares of Liquidia in the 4th quarter worth approximately $142,000. EntryPoint Capital LLC bought a new position in Liquidia in the 4th quarter worth $154,000. Finally, Walleye Trading LLC lifted its holdings in Liquidia by 54.7% during the third quarter. Walleye Trading LLC now owns 13,201 shares of the company's stock valued at $132,000 after purchasing an additional 4,670 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).